{"schema_version":"secwatch.filing_event.v1","accession":"0001814974-22-000024","form_type":"8-K","ticker":"BBXIB","cik":"0001814974","company_name":"BBX Capital, Inc.","filed_at":"2022-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.383623+00:00","generated_at":"2026-06-26T22:27:00.983453+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BBX Capital swings to Q4 net income of $5.3M; FY revenue $313.6M up 81%","bullets":["Q4 2021 total revenues $98.2M vs $56.2M; net income $5.3M vs ($3.5M) loss.","Full-year 2021 revenues $313.6M vs $173.2M; net income $46.9M vs ($42.3M) loss.","Diluted EPS from continuing ops $0.32 Q4 vs ($0.18); full-year $2.63 vs ($2.19).","BBXRE segment income before taxes $58.3M (FY) vs $10.0M; IT'SUGAR sales above 2019 pre-pandemic.","Renin segment loss before taxes narrowed to ($1.0M) from ($3.6M) despite supply chain headwinds."],"urls":{"canonical":"https://secwatch.observer/filing/0001814974-22-000024","json":"https://secwatch.observer/filing/0001814974-22-000024.json","markdown":"https://secwatch.observer/filing/0001814974-22-000024.md","text":"https://secwatch.observer/filing/0001814974-22-000024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1814974/000181497422000024/0001814974-22-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1814974/000181497422000024/c974-20220316x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T22:27:00.983453+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}